Effects of NG-nitro-L-arginine and/or L-arginine on experimental pulmonary metastasis in mice. 1994

T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
Department of Pathology, Center for Adult Diseases, Osaka, Japan.

Effects of NG-nitro-L-arginine methyl ester (L-NAME; an inhibitor of nitric oxide (NO) synthase) and/or L-arginine (substrate of NO synthase) on pulmonary metastasis of murine melanoma and Lewis lung carcinoma cells were investigated. L-NAME, L-arginine or both L-NAME and L-arginine was injected i.p. into mice 5, 3, and 1 h before and 1, 3, 5, and 7 h after the injection of tumor cells into mice via a tail vein. The administration of L-NAME (9.3 mumol/mouse) alone or L-arginine alone (46.5 or 186 mumol/mouse) potentiated pulmonary metastasis of highly and poorly metastatic B16 melanoma cells. L-NAME alone also increased the number of pulmonary metastasis of Lewis lung carcinoma cells, but L-arginine (185 mumol/mouse) did not. However, the combination of L-NAME and L-arginine increased the number of pulmonary metastasis of both the melanoma and Lewis lung carcinoma cells synergistically. L-NAME or L-arginine administration enhanced the retention of B16 melanoma cells in the lungs examined 24 h after the tumor cell injection. Synergistic effect of L-NAME and L-arginine was also seen in the tumor cell retention. The present results suggest that the metastatic potentials of the tumor cells do not simply correlate to NO production in vivo.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D013047 Specific Pathogen-Free Organisms Animals or humans raised in the absence of a particular disease-causing virus or other microorganism. Less frequently plants are cultivated pathogen-free. Pathogen-Free Organisms,Specific Pathogen Free,Organism, Pathogen-Free,Organism, Specific Pathogen-Free,Organisms, Pathogen-Free,Organisms, Specific Pathogen-Free,Pathogen Free Organisms,Pathogen Free, Specific,Pathogen Frees, Specific,Pathogen-Free Organism,Pathogen-Free Organism, Specific,Pathogen-Free Organisms, Specific,Specific Pathogen Free Organisms,Specific Pathogen-Free Organism

Related Publications

T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
November 1995, Methods and findings in experimental and clinical pharmacology,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
March 1993, Naunyn-Schmiedeberg's archives of pharmacology,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
December 1995, Clinical and experimental pharmacology & physiology. Supplement,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
July 1993, Japanese journal of pharmacology,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
April 1992, The Journal of physiology,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
February 1995, Clinical and experimental pharmacology & physiology,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
February 1994, Biochemical and biophysical research communications,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
October 1994, Journal of chromatography. B, Biomedical applications,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
October 1992, European journal of pharmacology,
T Yamamoto, and N Terada, and Y Nishizawa, and H Tanaka, and H Akedo, and A Seiyama, and T Shiga, and H Kosaka
October 1992, British journal of pharmacology,
Copied contents to your clipboard!